Published on 11 December 2024 This is to update all our stakeholders that the Health Technology Assessment (HTA) Division has completed the Philippine Guidance Document on the Use of Real-World Evidence in Clinical Assessment of Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Method Guides across different health technologies. continue reading : [FOR PUBLIC CONSULTATION] DRAFT Philippines Guidance Document for the Use of Real-World Evidence in Clinical Assessment of Health Technologies
CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – UPDATED Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments] [CLOSED]
Note: This call for proposals closed on 22 November 2024. This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments: The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – UPDATED Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments] [CLOSED]
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
Published on 01 October 2024 As of 23 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS
We would like to inform our stakeholders that the HTA Council will accept nominations only from the Department of Health (DOH) and Philippine Health Insurance Corporation (PhilHealth) in 2024, and open the Call for Nominations to other stakeholders in the 4th quarter of 2025 for Cycle 3 Topics based on the status of ongoing assessments. continue reading : STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS
[Announcement] Meeting with Stakeholders for the 2024 Provisional HTA Topic Prioritization List – Cycle 2 Topics on 23 April 2024
We are pleased to invite you to join the Meeting with Stakeholders for the 2024 Provisional HTA Topic Prioritization List – Cycle 2 Topics on 23 April 2024 (Tuesday) at 1:00-3:00 PM via Zoom teleconference. Kindly see the advisory for full details: bit.ly/SHMeetingProviList ————————————————————————– To keep updated on HTA news, visit our website: https://hta.dost.gov.ph/ Like and continue reading : [Announcement] Meeting with Stakeholders for the 2024 Provisional HTA Topic Prioritization List – Cycle 2 Topics on 23 April 2024